Opportunity Information: Apply for PAR 13 299
Apply for PAR 13 299
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Biomarkers Bridging Pediatric and Adult Therapeutics (R03)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Aug 1, 2013 and posted on Aug 1, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $50,000.00 in funding.
- Eligible applicants include: City or township governments Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments State governments Small businesses County governments For profit organizations other than small businesses Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Biomarkers Bridging Pediatric and Adult Therapeutics (R03) funding opportunity (PAR-13-299) is a National Institutes of Health (NIH) small grant program designed to speed up the translation of well-studied adult biomarkers into pediatric settings. The central idea is to close a common gap in child health research and clinical care: many biomarkers already have strong evidence and clear clinical meaning in adults, but they have not been adequately tested, validated, or adapted for use in children. Under this FOA, applicants are encouraged to propose projects that take adult biomarkers with a known relationship to a clinical observation and generate the pediatric evidence needed to support their use for diagnosis, prognosis, monitoring disease progression, evaluating toxicity, or predicting/assessing response to therapy in pediatric populations.
Projects must stay tightly focused on adaptation and validation rather than discovery. The FOA is explicitly limited to biomarkers that have been extensively studied in adults and for which there is solid evidence suggesting pediatric applicability. In other words, the program is not intended for exploratory work aimed at finding brand-new biomarkers, nor is it meant to support early-stage biomarker discovery efforts tied to preclinical studies or the development of new drugs. It also excludes biomarkers for diseases that are unique to children and lack adult correlates, because the purpose is specifically to leverage adult knowledge where there is a meaningful adult-pediatric bridge.
Administratively, this opportunity falls under the NIH discretionary grant category using the R03 mechanism, which is typically used for smaller, short, targeted projects that can generate useful preliminary or validation data. The award ceiling listed is $50,000, and there is no cost sharing or matching requirement. The FOA was posted on August 1, 2013, with an original and final closing date of September 7, 2016, and it was archived on October 8, 2016. The program is associated with CFDA 93.865 (Child Health and Human Development Extramural Research), reflecting its emphasis on pediatric research and the strengthening of evidence for child-focused clinical applications.
Eligibility is broad and includes many types of domestic and non-domestic applicants. Eligible applicants include state, county, city or township governments, special district governments, and independent school districts, as well as public housing authorities and Native American tribal governments and organizations (including federally recognized and other tribal entities). Nonprofit organizations (both 501(c)(3) and non-501(c)(3)), public and state-controlled institutions of higher education, private institutions of higher education, small businesses, and for-profit organizations other than small businesses are also eligible. The FOA further clarifies eligibility for a range of institutions and communities, including HBCUs, Hispanic-serving institutions, AANAPISI institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based and community-based organizations, and eligible federal agencies. Importantly, foreign organizations and foreign institutions are eligible to apply, and non-U.S. components of U.S. organizations may participate; foreign components are allowed as defined by the NIH Grants Policy Statement.
In practical terms, a strong application under this FOA would typically identify an adult biomarker with established clinical relevance, explain why there is credible reason to believe it should work in children (biological rationale, disease similarity across age groups, existing limited pediatric data, or clinical need), and then lay out a clear plan to validate or calibrate it for pediatric use. That could include demonstrating appropriate pediatric reference ranges, confirming associations with clinically meaningful outcomes in children, assessing age-dependent effects on biomarker levels, or establishing how well the biomarker tracks disease activity, toxicity, or treatment response in pediatric cohorts. The emphasis is on producing actionable pediatric evidence that can support better clinical decision-making and improve the alignment of pediatric therapeutics with the more mature biomarker landscape already available in adult medicine.
For full details, the archived announcement is linked here: http://grants.nih.gov/grants/guide/pa-files/PAR-13-299.html. For access issues, NIH lists the Office of Extramural Research (OER) webmaster contact at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs)
What is the Biomarkers Bridging Pediatric and Adult Therapeutics (R03) funding opportunity?
It is an NIH small grant program (R03 mechanism) intended to speed translation of well-studied adult biomarkers into pediatric settings by generating the pediatric evidence needed to support clinical use in children.
What is the FOA number and title?
The FOA is PAR-13-299, titled "Biomarkers Bridging Pediatric and Adult Therapeutics (R03)."
What is the main goal of this FOA?
The goal is to close a gap where biomarkers with strong evidence and clear clinical meaning in adults have not been adequately tested, validated, or adapted for pediatric use. Projects should produce actionable pediatric evidence to support clinical decision-making in children.
What kinds of biomarkers are appropriate for this program?
Biomarkers that have been extensively studied in adults and have a known relationship to a clinical observation, with solid evidence suggesting they may be applicable in pediatric populations.
Is this FOA intended for discovering new biomarkers?
No. Projects must stay tightly focused on adaptation and validation rather than discovery. The FOA is not intended for exploratory work to find brand-new biomarkers.
Can projects be tied to preclinical studies or new drug development?
No. The FOA is not meant to support early-stage biomarker discovery efforts tied to preclinical studies or the development of new drugs.
Are biomarkers for diseases unique to children eligible?
No. The FOA excludes biomarkers for diseases that are unique to children and lack adult correlates, because the purpose is specifically to leverage adult knowledge where a meaningful adult-pediatric bridge exists.
What pediatric uses of adult biomarkers does the FOA emphasize?
The FOA emphasizes generating pediatric evidence to support use for diagnosis, prognosis, monitoring disease progression, evaluating toxicity, and predicting or assessing response to therapy in pediatric populations.
What would a strong application generally include?
A strong application would typically (1) identify an adult biomarker with established clinical relevance, (2) explain why there is credible reason it should work in children (for example, biological rationale, disease similarity across age groups, limited existing pediatric data, or a clinical need), and (3) provide a clear plan to validate or calibrate the biomarker for pediatric use.
What are examples of validation or adaptation activities that fit this FOA?
Examples described in the opportunity include establishing pediatric reference ranges, confirming associations with clinically meaningful outcomes in children, assessing age-dependent effects on biomarker levels, and determining how well the biomarker tracks disease activity, toxicity, or treatment response in pediatric cohorts.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R03 mechanism, which is typically used for smaller, short, targeted projects that can generate useful preliminary or validation data.
What is the award ceiling?
The listed award ceiling is $50,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
When was the FOA posted, and what were the closing dates?
The FOA was posted on August 1, 2013. The original and final closing date was September 7, 2016.
Is this funding opportunity still open?
No. The FOA was archived on October 8, 2016.
Which CFDA program is this associated with?
The program is associated with CFDA 93.865 (Child Health and Human Development Extramural Research).
Who is eligible to apply?
Eligibility is broad and includes many domestic and non-domestic applicants. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public housing authorities; Native American tribal governments and organizations (including federally recognized and other tribal entities); nonprofit organizations (501(c)(3) and non-501(c)(3)); public and state-controlled institutions of higher education; private institutions of higher education; small businesses; and for-profit organizations other than small businesses.
Are foreign organizations or institutions eligible to apply?
Yes. Foreign organizations and foreign institutions are eligible. Non-U.S. components of U.S. organizations may participate, and foreign components are allowed as defined by the NIH Grants Policy Statement.
Are minority-serving institutions and community-based organizations included in eligibility?
Yes. The FOA explicitly clarifies eligibility for a range of institutions and communities, including HBCUs, Hispanic-serving institutions, AANAPISI institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, faith-based organizations, community-based organizations, and eligible federal agencies.
Where can I find the full archived announcement?
The archived announcement is available at http://grants.nih.gov/grants/guide/pa-files/PAR-13-299.html.
Who do I contact if I have trouble accessing the announcement?
NIH lists the Office of Extramural Research (OER) webmaster contact for access issues: FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Biomarkers Bridging Pediatric and Adult Therapeutics (R21)
Previous opportunity: FY 2014 Species Recovery Grants to Tribes
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 299
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 299) also looked into and applied for these:
| Funding Opportunity |
|---|
| Biomarkers Bridging Pediatric and Adult Therapeutics (R21) Apply for PAR 13 295 Funding Number: PAR 13 295 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Biomarkers Bridging Pediatric and Adult Therapeutics (R01) Apply for PAR 13 296 Funding Number: PAR 13 296 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01) Apply for PAR 13 309 Funding Number: PAR 13 309 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03) Apply for PAR 13 310 Funding Number: PAR 13 310 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21) Apply for PAR 13 311 Funding Number: PAR 13 311 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01) Apply for PAR 13 325 Funding Number: PAR 13 325 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21) Apply for PAR 13 326 Funding Number: PAR 13 326 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R03) Apply for PAR 13 344 Funding Number: PAR 13 344 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R43) Apply for PAR 13 345 Funding Number: PAR 13 345 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems STTR (R41) Apply for PAR 13 346 Funding Number: PAR 13 346 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Sustained Release of Antivirals for Treatment and Prevention of HIV (SRATP) (R01) Apply for PAR 13 349 Funding Number: PAR 13 349 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Enhancing the Capacity for Biomedical Research on Tuberculosis for HIV infected Mothers and Children in India (R01) Apply for RFA HD 14 025 Funding Number: RFA HD 14 025 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $350,000 |
| Developmental Origins of Health and Disease (DOHaD) Epigenetic Modification in Gametogenesis and Transgenerational Inheritance (R01) Apply for PAR 13 385 Funding Number: PAR 13 385 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Female Contraceptive Development Program (U01) Apply for RFA HD 14 024 Funding Number: RFA HD 14 024 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $250,000 |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (SBIR) (R43/R44) Apply for RFA HD 14 031 Funding Number: RFA HD 14 031 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01) Apply for PAR 13 389 Funding Number: PAR 13 389 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (STTR) (R41/R42) Apply for RFA HD 14 032 Funding Number: RFA HD 14 032 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Centers for Collaborative Research in Fragile X (U54) Apply for RFA HD 14 033 Funding Number: RFA HD 14 033 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $1,300,000 |
| Juvenile Protective Factors and Their Effects on Aging (R03) Apply for PAR 14 022 Funding Number: PAR 14 022 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| U.S South Africa Program for Collaborative Biomedical Research (U01) Apply for RFA AI 14 018 Funding Number: RFA AI 14 018 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $225,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 299", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.